Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Netherlands

European Innovation Council · Running

REPRESSIT REPRESSIT: A novel class of clinical immune checkpoint inhibitors

Coordinator
Stichting Nederlandse Wetenschappelijk Onderzoek Instituten, Netherlands
Runs
1 May 2023 to 30 April 2028
Status
Running
EU funding
€2.9m
Total cost
€2.9m
Partners
6 organisations in 4 countries
Type
European Innovation Council
Grant agreement
101098965

What the project is doing

In the project's own words, from its summary on CORDIS.

In the tumor microenvironment, continuous or “tonic” stimulation of T cells induces checkpoint signaling through inhibitory immune receptors (IRs). This phenomenon suppresses T cell function, contributing to an exhaustion phenotype and their consequent failure to eliminate cancer cells. Checkpoint blockade through IR-targeting antibodies (e.g. anti-PD-1, anti-CTLA-4) can partially reverse this process, and has revolutionized cancer immunotherapy.

However, a large fraction of patients, e.g. with tumors that do not express IR ligands, do not benefit from this treatment. Thus, a large unmet need remains to be addressed. We aim to change the current ligand-centric “blockade” paradigm. The REPRESSIT platform technology developed herein will provide a radically new approach, through development of a novel class of ligand-independent checkpoint therapeutics. These Receptor Inhibition by Phosphatase Recruitment (RIPR) molecules recruit tyrosine phosphatases to the IR and shut down IR signaling, thereby reactivating exhausted T or NK cells to effectively clear cancer cells.

The REPRESSIT consortium unites unique complementary expertise and models in IR biology, tumor immunology, protein engineering, biophysics and proteomics, to: 1) define the design principles of RIPR molecules against multiple checkpoint IR targets, 2) evaluate the IR mode of action of signal inhibition, 3) optimize RIPR molecule for their efficacy using preclinical cancer models, and 4) demonstrate in vivo proof-of-concept (PoC)), focusing on a highly-relevant panel of T and NK cell IRs known to display tonic signaling.

REPRESSIT will deliver a technology platform for off-the-shelf RIPR designs targeting phosphotyrosine-carrying IR. This project will provide the foundation for our long-term vision of innovative immune checkpoint therapeutics with unprecedented efficacy and provide a greatly improved perspective to the many cancer patients for which current treatment is ineffective.

Topics

Who is involved

OrganisationCityCountryRole
Stichting Nederlandse Wetenschappelijk Onderzoek InstitutenUtrechtNetherlandsCoordinator
Universitatsklinikum BonnBonnGermanyParticipant
Universitair Medisch Centrum UtrechtUtrechtNetherlandsParticipant
Karolinska InstitutetStockholmSwedenParticipant
Vycellix Sweden ABStockholmSwedenParticipant
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI